1.
|
Gustavsson H, Welen K and Damber JE:
Transition of an androgen-dependent human prostate cancer cell line
into an androgen-independent subline is associated with increased
angiogenesis. Prostate. 62:364–373. 2005. View Article : Google Scholar : PubMed/NCBI
|
2.
|
Niu Y, Altuwaijri S, Lai KP, et al:
Androgen receptor is a tumor suppressor and proliferator in
prostate cancer. Proc Natl Acad Sci USA. 105:12182–12187. 2008.
View Article : Google Scholar : PubMed/NCBI
|
3.
|
Lee SO, Dutt SS, Nadiminty N, Pinder E,
Liao H and Gao AC: Development of an androgen-deprivation induced
and androgen suppressed human prostate cancer cell line. Prostate.
67:1293–1300. 2007. View Article : Google Scholar : PubMed/NCBI
|
4.
|
Saraon P, Jarvi K and Diamandis EP:
Molecular alterations during progression of prostate cancer to
androgen independence. Clin Chem. 57:1366–1375. 2011. View Article : Google Scholar : PubMed/NCBI
|
5.
|
Devlin HL and Mudryj M: Progression of
prostate cancer: multiple pathways to androgen independence. Cancer
Lett. 274:177–186. 2009. View Article : Google Scholar : PubMed/NCBI
|
6.
|
Watson PA, Chen YF, Balbas MD, et al:
Constitutively active androgen receptor splice variants expressed
in castration-resistant prostate cancer require full-length
androgen receptor. Proc Natl Acad Sci USA. 107:16759–16765. 2010.
View Article : Google Scholar
|
7.
|
Hendriksen PJ, Dits NF, Kokame K, et al:
Evolution of the androgen receptor pathway during progression of
prostate cancer. Cancer Res. 66:5012–5020. 2006. View Article : Google Scholar : PubMed/NCBI
|
8.
|
Lorenzo GD, Bianco R, Tortora G and
Ciardiello F: Involvement of growth factor receptors of the
epidermal growth factor receptor family in prostate cancer
development and progression to androgen independence. Clin Prostate
Cancer. 2:50–57. 2003. View Article : Google Scholar : PubMed/NCBI
|
9.
|
Maeda A, Nakashiro K, Hara S, et al:
Inactivation of AR activates HGF/c-Met system in human prostatic
carcinoma cells. Biochem Biophys Res Commun. 347:1158–1165. 2006.
View Article : Google Scholar : PubMed/NCBI
|
10.
|
Nishida S, Hirohashi Y, Torigoe T, et al:
Prostate cancer stem-like cells/cancer-initiating cells have an
autocrine system of hepatocyte growth factor. Cancer Sci.
104:431–436. 2013. View Article : Google Scholar : PubMed/NCBI
|
11.
|
Matsumoto K and Nakamura T: Emerging
multipotent aspects of hepatocyte growth factor. J Biochem.
119:591–600. 1996. View Article : Google Scholar : PubMed/NCBI
|
12.
|
Verras M, Lee J, Xue H, Li TH, Wang Y and
Sun Z: The androgen receptor negatively regulates the expression of
c-Met: implications for a novel mechanism of prostate cancer
progression. Cancer Res. 67:967–975. 2007. View Article : Google Scholar : PubMed/NCBI
|
13.
|
Christensen JG, Burrows J and Salgia R:
c-Met as a target for human cancer and characterization of
inhibitors for therapeutic intervention. Cancer Lett. 225:1–26.
2005. View Article : Google Scholar : PubMed/NCBI
|
14.
|
Gherardi E, Birchmeier W, Birchmeier C and
Vande Woude G: Targeting MET in cancer: rationale and progress. Nat
Rev Cancer. 12:89–103. 2012. View
Article : Google Scholar : PubMed/NCBI
|
15.
|
Peruzzi B and Bottaro DP: Targeting the
c-Met signaling pathway in cancer. Clin Cancer Res. 12:3657–3660.
2006. View Article : Google Scholar : PubMed/NCBI
|
16.
|
Liu T, Wu LY, Fulton MD, Johnson JM and
Berkman CE: Prolonged androgen deprivation leads to downregulation
of androgen receptor and prostate-specific membrane antigen in
prostate cancer cells. Int J Oncol. 41:2087–2092. 2012.PubMed/NCBI
|
17.
|
Liu T, Wu LY, Hopkins MR, Choi JK and
Berkman CE: A targeted low molecular weight near-infrared
fluorescent probe for prostate cancer. Bioorg Med Chem Lett.
20:7124–7126. 2010. View Article : Google Scholar : PubMed/NCBI
|
18.
|
Matroule JY, Carthy CM, Granville DJ,
Jolois O, Hunt DW and Piette J: Mechanism of colon cancer cell
apoptosis mediated by pyropheophorbide-a methylester
photosensitization. Oncogene. 20:4070–4084. 2001. View Article : Google Scholar : PubMed/NCBI
|
19.
|
Liu T, Wu LY and Berkman CE:
Prostate-specific membrane antigen-targeted photodynamic therapy
induces rapid cytoskeletal disruption. Cancer Lett. 296:106–112.
2010. View Article : Google Scholar : PubMed/NCBI
|
20.
|
Liu T, Toriyabe Y and Berkman CE:
Purification of prostate-specific membrane antigen using
conformational epitope-specific antibody-affinity chromatography.
Protein Expr Purif. 49:251–255. 2006. View Article : Google Scholar
|
21.
|
Wolf DA, Herzinger T, Hermeking H,
Blaschke D and Horz W: Transcriptional and posttranscriptional
regulation of human androgen receptor expression by androgen. Mol
Endocrinol. 7:924–936. 1993.PubMed/NCBI
|
22.
|
Hu P, Chu GC, Zhu G, et al: Multiplexed
quantum dot labeling of activated c-Met signaling in
castration-resistant human prostate cancer. PLoS One. 6:e286702011.
View Article : Google Scholar : PubMed/NCBI
|
23.
|
Suzuki H, Ueda T, Ichikawa T and Ito H:
Androgen receptor involvement in the progression of prostate
cancer. Endocr Relat Cancer. 10:209–216. 2003. View Article : Google Scholar : PubMed/NCBI
|
24.
|
Smith DC, Smith MR, Sweeney C, et al:
Cabozantinib in patients with advanced prostate cancer: results of
a phase II randomized discontinuation trial. J Clin Oncol.
31:412–419. 2013. View Article : Google Scholar
|
25.
|
Humphrey PA, Zhu X, Zarnegar R, et al:
Hepatocyte growth factor and its receptor (c-MET) in prostatic
carcinoma. Am J Pathol. 147:386–396. 1995.PubMed/NCBI
|
26.
|
Colombel M, Eaton CL, Hamdy F, et al:
Increased expression of putative cancer stem cell markers in
primary prostate cancer is associated with progression of bone
metastases. Prostate. 72:713–720. 2012. View Article : Google Scholar : PubMed/NCBI
|